Yaghmaie Marjan, Alimoghaddam Kamran, Mozdarani Hossein, Ghavamzadeh Ardeshir, Hajhashemi Marjan, Aznab Mozaffar, Ghaffari Seyed H
Dept. of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modarres University, P. O. Box 14115-111, Tehran.
Haematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Iran Biomed J. 2012;16(1):10-7. doi: 10.6091/ibj.961.2012.
The secondary genetic changes other than the promyelocytic leukemia-retinoic acid receptor (PML-RARA) fusion gene may contribute to the acute promyelocytic leukemogenesis. Chromosomal alterations and mutation of FLT3 (FMS-like tyrosine kinase 3) tyrosine kinase receptor are the frequent genetic alterations in acute myeloid leukemia. However, the prognostic significance of FLT3 mutations in acute promyelocytic leukemia (APL) is not firmly established.
In this study, the chromosomal abnormalities were analyzed by bone marrow cytogenetic in 45 APL patients and FLT3 internal tandem duplications (ITD) screening by fragment length analysis and FLT3 D835 mutation by melting curve analysis were screened in 23 APL samples.
Cytogenetic study showed 14.3% trisomy 8 and 17.1% chromosomal abnormalities other than t(15;17). About 13% of the patients had FLT3 ITD, and 26% had D835 point mutation. FLT3 ITD mutation was associated with higher white blood cell count at presentation and poor prognosis.
The PML-RARA translocation alone may not be sufficient to induce leukemia. Therefore, we assume that FLT3 mutations and the other genetic and chromosomal alterations may cooperate with PML-RARA in the development of APL disease.
除早幼粒细胞白血病-维甲酸受体(PML-RARA)融合基因外的继发性基因改变可能参与急性早幼粒细胞白血病的发生。染色体改变以及FMS样酪氨酸激酶3(FLT3)酪氨酸激酶受体的突变是急性髓系白血病常见的基因改变。然而,FLT3突变在急性早幼粒细胞白血病(APL)中的预后意义尚未明确确立。
在本研究中,对45例APL患者进行骨髓细胞遗传学分析以检测染色体异常,并对23例APL样本进行片段长度分析筛查FLT3内部串联重复(ITD)以及通过熔解曲线分析筛查FLT3 D835突变。
细胞遗传学研究显示,8号染色体三体占14.3%,除t(15;17)外的染色体异常占17.1%。约13%的患者存在FLT3 ITD,26%存在D835点突变。FLT3 ITD突变与初诊时较高的白细胞计数及不良预后相关。
单独的PML-RARA易位可能不足以诱发白血病。因此,我们推测FLT3突变以及其他基因和染色体改变可能在APL疾病发生过程中与PML-RARA协同作用。